These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36402940)

  • 61. Economic Burden of Generalized Pustular Psoriasis in Sweden: A Population-Based Register Study.
    Löfvendahl S; Norlin JM; Schmitt-Egenolf M
    Psoriasis (Auckl); 2022; 12():89-98. PubMed ID: 35548662
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Early Discontinuation of Apremilast in Patients with Psoriasis and Gastrointestinal Comorbidities: Rates and Associated Risk Factors.
    Schmidt L; Wang CA; Patel V; Davidson D; Kalirai S; Panda A; Seigel L
    Dermatol Ther (Heidelb); 2023 Sep; 13(9):2019-2030. PubMed ID: 37517029
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Humanistic and Economic Burden of Patients with Cardiorenal Metabolic Conditions: A Systematic Review.
    Ferdinand KC; Norris KC; Rodbard HW; Trujillo JM
    Diabetes Ther; 2023 Dec; 14(12):1979-1996. PubMed ID: 37751142
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A retrospective analysis of disease epidemiology, comorbidities, treatment patterns, and healthcare resource utilization of alopecia areata in the United Arab Emirates using claims database.
    Hammadi AA; Parmar NV; Farghaly M; Dallal SA; Zayed MWA; Ebeid F; Subramanyam K; Ramachandrachar BC; Ahmed HM
    J Dermatol; 2024 Jul; ():. PubMed ID: 39051178
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The economic burden of HIV-associated wasting in the era of modern antiretroviral therapy.
    Siddiqui J; Samuel SK; Hayward B; Wirka KA; Deering KL; Harshaw Q; Phillips A; Harbour M
    J Manag Care Spec Pharm; 2022 Oct; 28(10):1180-1189. PubMed ID: 35939048
    [No Abstract]   [Full Text] [Related]  

  • 66. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
    Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
    J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Healthcare Resource Utilization and Direct Cost of Patients with Atopic Dermatitis in Dubai, United Arab Emirates: A Retrospective Cohort Study.
    Al Hammadi A; Pakran J; Farghaly M; Ahmed HM; Cha A; Balkan D; Afifi S; Ramachandrachar BC; Natarajan A; Linga S; Al Jefri K
    Dermatol Ther (Heidelb); 2022 Jul; ():1-25. PubMed ID: 35875408
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Economic burden of sarcoidosis in a commercially-insured population in the United States.
    Rice JB; White A; Lopez A; Conway A; Wagh A; Nelson WW; Philbin M; Wan GJ
    J Med Econ; 2017 Oct; 20(10):1048-1055. PubMed ID: 28678623
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Diabetic peripheral neuropathy: resource utilization and burden of illness.
    Mehra M; Merchant S; Gupta S; Potluri RC
    J Med Econ; 2014 Sep; 17(9):637-45. PubMed ID: 24888404
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US.
    Crown WH; Bresnahan BW; Orsini LS; Kennedy S; Leonardi C
    Curr Med Res Opin; 2004 Dec; 20(12):1929-36. PubMed ID: 15701211
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Neuromyelitis Optica Spectrum Disorder: Clinical Burden and Cost of Relapses and Disease-Related Care in US Clinical Practice.
    Royston M; Kielhorn A; Weycker D; Shaff M; Houde L; Tanvir I; Bhattacharyya S; Levy M
    Neurol Ther; 2021 Dec; 10(2):767-783. PubMed ID: 34046846
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Healthcare resource utilization, total costs, and comorbidities among patients with myotonic dystrophy using U.S. insurance claims data from 2012 to 2019.
    Howe SJ; Lapidus D; Hull M; Yeaw J; Stevenson T; Sampson JB
    Orphanet J Rare Dis; 2022 Feb; 17(1):79. PubMed ID: 35197080
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Rethinking costs of psoriasis: 10% of patients account for nearly 40% of healthcare expenditures among enrollees with psoriasis in a U.S. health plan.
    Armstrong AW; Zhao Y; Herrera V; Li Y; Bancroft T; Hull M; Altan A
    J Dermatolog Treat; 2017 Nov; 28(7):613-622. PubMed ID: 28320213
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Economic burden of fatigue or morning stiffness among patients with rheumatoid arthritis: a retrospective analysis from real-world data.
    Strand V; Shah R; Atzinger C; Zhou J; Clewell J; Ganguli A; Tundia N
    Curr Med Res Opin; 2020 Jan; 36(1):161-168. PubMed ID: 31433680
    [No Abstract]   [Full Text] [Related]  

  • 75. Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States.
    Atallah EL; Maegawa R; Latremouille-Viau D; Rossi C; Guérin A; Wu EQ; Patwardhan P
    J Health Econ Outcomes Res; 2022; 9(2):19-29. PubMed ID: 35979528
    [No Abstract]   [Full Text] [Related]  

  • 76. Determining the cost of obesity and its common comorbidities from a commercial claims database.
    Padula WV; Allen RR; Nair KV
    Clin Obes; 2014 Feb; 4(1):53-8. PubMed ID: 25425133
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Hidradenitis Suppurativa and Concurrent Psoriasis: Comparison of Epidemiology, Comorbidity Profiles, and Risk Factors.
    Pinter A; Kokolakis G; Rech J; Biermann MHC; Häberle BM; Multmeier J; Reinhardt M
    Dermatol Ther (Heidelb); 2020 Aug; 10(4):721-734. PubMed ID: 32500484
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Treatment patterns, comorbidities, healthcare resource use, and associated costs by line of chemotherapy and level of comorbidity in patients with newly-diagnosed Merkel cell carcinoma in the United States.
    Kearney M; Thokagevistk K; Boutmy E; Bharmal M
    J Med Econ; 2018 Dec; 21(12):1159-1171. PubMed ID: 30149739
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004-2015.
    Jiang M; Near AM; Desta B; Wang X; Hammond ER
    Lupus Sci Med; 2021 Sep; 8(1):. PubMed ID: 34521733
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Healthcare Resource Utilization and Direct Cost of Patients with Atopic Dermatitis in Dubai, United Arab Emirates: A Retrospective Cohort Study.
    Al Hammadi A; Pakran J; Farghaly M; Ahmed HM; Cha A; Balkan D; Afifi S; Ramachandrachar BC; Natarajan A; Linga S; Al Jefri K
    Dermatol Ther (Heidelb); 2022 Aug; 12(8):1859-1883. PubMed ID: 35851651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.